Olanzapine optimal dose: Results of an open-label multicenter study in schizophrenic patients

被引:15
作者
Ishigooka, J [1 ]
Murasaki, M [1 ]
Miura, S [1 ]
机构
[1] Kitasato Univ, Sch Med, Dept Psychiat, Sagamihara, Kanagawa 2288520, Japan
关键词
atypical antipsychotic; clinical open-label trial; olanzapine; optimal dose; schizophrenia;
D O I
10.1046/j.1440-1819.2000.00738.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
This open-label clinical study was conducted for patients with schizophrenia in order to investigate the efficacy, safety and optimal dose of olanzapine. One hundred and fifty-six of the 159 enrolled patients were included in the analysis set. For the primary efficacy measure, the Final Global Improvement Rating (FGIR) score, 15.4% of patients had remarkable improvement, 58.3% of patients had moderate improvement or more, 79.5% of patients had slight improvement or more, and 10.3% of patients had increase in disease symptomatology (worsening). Results from the Brief Psychiatric Rating Scale (BPRS) in all individual items were improved from baseline. Olanzapine was effective not only against positive psychotic symptoms but also against negative symptoms. This was consistent with results from the Positive and Negative Syndrome Scale (PANSS). For the majority of patients, a dose range of 7.5-10.0 mg/day, as a lower bound on the minimally effective dose, was suggested by the results of the dose to first response based on improvement in Global Improvement Rating (GIR) analyses. The ratio of olanzapine dose to equivalent haloperidol dose was estimated at 1.2:1. The most commonly reported treatment-emergent signs and symptoms (TESS) occurring at a frequency of 10% or more were insomnia, weight increase, excitement, sleepiness, anxiety, malaise and dull headaches. There was a low incidence of extrapyramidal treatment-emergent signs and symptoms; the most commonly reported were akathisia (6.4%), tremor (5.8%) and muscle rigidity (2.6%).
引用
收藏
页码:467 / 478
页数:12
相关论文
共 27 条
  • [11] Guy W., 1976, Guy, W. (1976). ECDEU Assessment Manual for Psychopharmacology-Revised. Rockville, MD, U.S. Department of Health, Education, and Welfare, Public health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, DHEW Publ No ADM 76-338, pp 218-222., P218
  • [12] Hamilton SH, 1998, NEUROPSYCHOPHARMACOL, V18, P41
  • [13] ISHIGOOKA J, 1999, JPN J CLIN PSYCHOPHA, V2, P353
  • [14] KUDO Y, 1998, J CLIN THERAPEUTIC M, V14, P2527
  • [15] KUDO Y, 1994, JPN J CLIN PSYCHIAT, V23, P223
  • [16] LEADBETTER R, 1992, AM J PSYCHIAT, V149, P68
  • [17] *MED EC CO INC, 2000, PHYS DESK REF, P2008
  • [18] MELTZER HY, 1992, NOVEL ANTIPSYCHOTIC DRUGS, P1
  • [19] Murasaki M., 1993, CLIN EVAL, V21, P221
  • [20] Olanzapine-induced agranulocytosis
    Naumann, R
    Felber, W
    Heilemann, H
    Reuster, T
    [J]. LANCET, 1999, 354 (9178) : 566 - 567